Log in

NASDAQ:IBBiShares Nasdaq Biotechnology ETF Stock Price, Forecast & News

$139.21
-1.36 (-0.97 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$138.62
Now: $139.21
$140.87
50-Day Range
$127.41
MA: $134.51
$140.57
52-Week Range
$92.15
Now: $139.21
$142.33
Volume2.91 million shs
Average Volume3.31 million shs
Market Capitalization$9.84 billion
P/E RatioN/A
Dividend Yield0.22%
Beta1.19
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.
Read More
iShares Nasdaq Biotechnology ETF logo

Geographic Exposure of IBB

Currency Exposure of IBB

Sector Exposure of IBB

Industry Exposure of IBB


Basic Details

Issuer BlackRock
Fund NameiShares Nasdaq Biotechnology ETF
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:IBB
Inception Date2/5/2001
Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkNASDAQ Biotechnology Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$7.70 billion
Average Daily Volume$2.62 million
Discount/Premium0.08%

ETF Expenses

Management Fee0.47%
Other Expenses0.00%
Total Expenses0.47%
Fee Waiver0.00%
Net Expenses0.47%

Administrator, Advisor and Custodian

AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial

Receive IBB News and Ratings via Email

Sign-up to receive the latest news and ratings for IBB and its competitors with MarketBeat's FREE daily newsletter.

iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Frequently Asked Questions

How has iShares Nasdaq Biotechnology ETF's stock been impacted by COVID-19 (Coronavirus)?

iShares Nasdaq Biotechnology ETF's stock was trading at $106.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IBB shares have increased by 30.1% and is now trading at $139.21. View which stocks have been most impacted by Coronavirus.

How often does iShares Nasdaq Biotechnology ETF pay dividends? What is the dividend yield for iShares Nasdaq Biotechnology ETF?

iShares Nasdaq Biotechnology ETF declared a quarterly dividend on Wednesday, March 25th. Shareholders of record on Thursday, March 26th will be given a dividend of $0.0554 per share on Tuesday, March 31st. This represents a $0.22 dividend on an annualized basis and a dividend yield of 0.16%. The ex-dividend date of this dividend is Wednesday, March 25th. View iShares Nasdaq Biotechnology ETF's dividend history.

When did iShares Nasdaq Biotechnology ETF's stock split? How did iShares Nasdaq Biotechnology ETF's stock split work?

iShares Nasdaq Biotechnology ETF shares split before market open on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly minted shares were distributed to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of iShares Nasdaq Biotechnology ETF stock prior to the split would have 300 shares after the split.

Has iShares Nasdaq Biotechnology ETF been receiving favorable news coverage?

News stories about IBB stock have been trending neutral on Sunday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. iShares Nasdaq Biotechnology ETF earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave news stories about the financial services provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about iShares Nasdaq Biotechnology ETF.

Who are some of iShares Nasdaq Biotechnology ETF's key competitors?

What other stocks do shareholders of iShares Nasdaq Biotechnology ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Nasdaq Biotechnology ETF investors own include NVIDIA (NVDA), Alibaba Group (BABA), Walt Disney (DIS), Netflix (NFLX), Bank of America (BAC), Tesla (TSLA), Cisco Systems (CSCO), Gilead Sciences (GILD), Micron Technology (MU) and Boeing (BA).

Who are iShares Nasdaq Biotechnology ETF's key executives?

iShares Nasdaq Biotechnology ETF's management team includes the following people:
  • George G. C. Parker Ph.D., Independent Chairman of the Board of Trustees
  • Michael Arthur Latham, President, Trustee
  • Jack Gee, Chief Financial Officer, Treasurer
  • Geoffrey D. Flynn, Chief Operating Officer, Executive Vice President
  • , Bio & Compensation - 
  • Amy Schioldager, Executive Vice President
  • Ira P. Shapiro, Vice President, Chief Legal Officer
  • Matt Tucker, Vice President
  • , Bio & Compensation - 
  • Eilleen M. Clavere, Secretary
  • Cecilia H. Herbert, Independent Trustee
  • Charles A. Hurty, Independent Trustee

What is iShares Nasdaq Biotechnology ETF's stock symbol?

iShares Nasdaq Biotechnology ETF trades on the NASDAQ under the ticker symbol "IBB."

Who are iShares Nasdaq Biotechnology ETF's major shareholders?

iShares Nasdaq Biotechnology ETF's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.60%), Chesley Taft & Associates LLC (0.06%), M&R Capital Management Inc. (0.05%), EWG Elevate Inc. (0.04%), Burns J W & Co. Inc. NY (0.04%) and Bay Rivers Group (0.03%).

Which major investors are selling iShares Nasdaq Biotechnology ETF stock?

IBB stock was sold by a variety of institutional investors in the last quarter, including Fulton Bank N. A., Clarus Wealth Advisors, Chesley Taft & Associates LLC, Wiley BROS. Aintree Capital LLC, Acorn Financial Advisory Services Inc. ADV, Whittier Trust Co. of Nevada Inc., Burns J W & Co. Inc. NY, and ELM Advisors LLC.

Which major investors are buying iShares Nasdaq Biotechnology ETF stock?

IBB stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., EWG Elevate Inc., Platte River Wealth Advisors LLC, Tatro Capital LLC, M&R Capital Management Inc., Carroll Financial Associates Inc., N.E.W. Advisory Services LLC, and Tsfg LLC.

How do I buy shares of iShares Nasdaq Biotechnology ETF?

Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is iShares Nasdaq Biotechnology ETF's stock price today?

One share of IBB stock can currently be purchased for approximately $139.21.

How big of a company is iShares Nasdaq Biotechnology ETF?

iShares Nasdaq Biotechnology ETF has a market capitalization of $9.84 billion.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.